Inhibrx, Inc. INBX · Stock Open Inhibrx, Inc. in new tab
Inhibrx, Inc. Analysis (INBX)
Is Inhibrx, Inc. a good investment? Inhibrx, Inc. (INBX) is currently trading at 93.38 USD.
Earnings Schedule: Inhibrx, Inc. is expected to release its next earnings report on Nov. 13, 2026. The market consensus estimate for Forward EPS is -8.76.
Investor FAQ
Does Inhibrx, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Inhibrx, Inc.?
Inhibrx, Inc. is classified as a Stock.
When is the next earnings date?
The next earnings date is projected to be Nov. 13, 2026. The company currently has a trailing EPS of -8.88.
Company Profile
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Community Discussion